小干扰RNA
脂肪性肝炎
疾病
医学
癌症研究
内体
细胞内
生物信息学
翻译(生物学)
生物
遗传增强
核酸
计算生物学
小RNA
核糖核酸
RNA干扰
肝病
脂肪肝
炎症
临床实习
细胞生物学
癌症
PARP1
代谢途径
药理学
从长凳到床边
寡核苷酸
调解人
基因沉默
脂肪变性
临床试验
标识
DOI:10.1016/j.bbrep.2026.102817
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), is driven by interacting genetic, metabolic, inflammatory, and fibrogenic processes that complicate therapeutic development. Small interfering RNA (siRNA) is an emerging modality for sequence-specific suppression of genetically supported targets and intracellular proteins that are difficult to modulate with conventional drugs. Chemical modification and liver-directed delivery have improved siRNA stability and hepatic exposure. However, most MASH-directed programs remain preclinical or in early clinical development, and human data have not established consistent histological benefit. Major limitations include delivery to nonparenchymal cells, inefficient endosomal escape, off-target effects, immunogenicity, and uncertain long-term safety. This review critically evaluates target selection, delivery, clinical and preclinical evidence, unsuccessful programs, competing nucleic acid modalities, and combination strategies. The clinical role of siRNA in MASH remains to be established.
科研通智能强力驱动
Strongly Powered by AbleSci AI